Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice

Yu Chen1,2, Yanqing Pei2, Jingyu Luo2, Zhaoqin Huang3, Jinming Yu1,2* and Xiangjiao Meng1,2*

1 Cheeloo College of Medicine, Shandong University, Jinan, China, 2 Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, 3 Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China

Programmed cell death protein-1/ligand 1 (PD-1/L1) targeted immune checkpoint inhibitors have become the focus of tumor treatment due to their promising efficacy. Currently, several PD-1/PD-L1 inhibitors have been approved for clinical practice with several more in clinical trials. Notably, based on available trial data, the selection of different PD-1/PD-L1 inhibitors in the therapeutic application and the corresponding efficacy varies. Widespread attention then is increasingly raised to the clinical comparability of different PD-1/PD-L1 inhibitors. The comparison of the inhibitors could not only help clinicians make in-depth understanding of them, but also further facilitate the selection of the optimal inhibitor for patients in treatment as well as for future clinical research and the development of new related drugs. As we all know, molecular structure could determine molecular function, which further affects their application. Therefore, in this review, we aim to comprehensively compare the structural basis, molecular biological functions, and clinical practice of different PD-1/PD-L1 inhibitors.

Keywords: PD-1 inhibitors, PD-L1 inhibitors, comparison, differences, optimal treatment, efficacy

BACKGROUND

PD-1/PD-L1 inhibitors have created a paradigm shift in cancer immunotherapy. Binding of PD-1 to its ligand PD-L1 can trigger an inhibitory signal, leading to reduced T-cell proliferation, and anti-tumor immunity. Blocking the binding of PD-1 to PD-L1, has been shown to reinvigorate T-cell activity and the anti-tumor immune response, which supports the rationale for PD-1/PD-L1 inhibitors as promising therapeutics. Until now, PD-1 inhibitors (nivolumab and pembrolizumab) and PD-L1 inhibitors (atezolizumab, avelumab, and durvalumab) have been approved by the US Food and Drug Administration (FDA) for the treatment of a wide spectrum of tumors, including NSCLC, urothelial cancer, melanoma, head and neck squamous cell cancer, and lymphoma (1). In addition, a number of newly engineered PD-1/PD-L1 inhibitors are undergoing clinical trials in the hope of achieving improved clinical outcomes (2–4).
Because a variety of PD-1/PD-L1 inhibitors are available for cancer treatment, it is of great clinical significance to have a comprehensive understanding of the potential differences between these agents, to enable the selection and development of optimal treatments. Here, we illustrate the rationale of action mechanism, describe the structural basis of the PD-1 and PD-L1 inhibitors, IgG4 and IgG1, respectively, make a comparison in terms of their molecular structure, biological function, and clinical perspectives and further highlight future research needs to achieve optimal patient management and the development of new related drugs.

**RATIONALE OF PD-1/PD-L1 INHIBITORS**

Tumor-specific cytotoxic T cells are capable of recognizing cancer neoantigens, further inducing tumor cell death through direct killing, and the release of inflammatory mediators. During this process, it has been found that activated T cells upregulate the expression of PD-1 on their surface. PD-1 is a monomorphic type I immune inhibitory transmembrane receptor, mainly expressed in T cells, B cells, natural killer cells, and many other tumor-infiltrating lymphocytes (5). Likewise, the PD-1 ligand, PD-L1, is a type I transmembrane protein, normally expressed on antigen-presenting cells as well as non-immune cells, such as Kupffer cells and epithelial cells (6, 7). Generally, the interaction between PD-1 and PD-L1 not only prevents excessive lymphocyte activation and achieves immune tolerance to self-antigens, but it also downregulates the anti-tumor function of T cells, thus leading to tumor immune escape (5, 8). Therefore, it has been observed that most tumors upregulate PD-L1 expression in response to interferon-γ (IFN-γ) and other inflammatory mediators, thus delivering enhanced inhibitory signals to T cells and resulting in poor survival rates (9). Overactivation of the PD-1/PD-L1 pathway in tumors and the resulting poor patient survival rates, makes this pathway a feasible target for antibody treatment (Figure 1).

PD-1/PD-L1 inhibitors are used to shift the balance toward immune activation, further enhancing tumor immunosurveillance, and anti-tumor immune responses. PD-1 inhibitors interact with PD-1 through overlapping surface regions, which prevents the binding of PD-L1 or PD-L2 to PD-1 (10). Nivolumab and pembrolizumab are the two most representative PD-1 inhibitors that have already been approved by the US FDA for the clinical treatment of a variety of tumors (11). Besides, many other PD-1 inhibitors, such as sintilimab, tislelizumab and camrelizumab (SHR-1210) are currently being studied in clinical trials and have achieved significant survival benefits (2, 3, 12). Anti-PD-L1 monoclonal antibodies inhibit the binding of PD-L1 with PD-1 and B7-1 on T cells (13, 14). Up to now, atezolizumab, durvalumab, and avelumab are the most promising PD-L1-targeting drugs for cancer treatment (11).

**IGG, THE MOLECULAR STRUCTURE BASIS OF PD-1/PD-L1 INHIBITORS**

IgGs are made up of two heavy chains and two light chains, which connect to each other by inter-chain disulfide bridges (Figure 2). Based on enzymatic digestion with papain, an antibody can also be divided into two Fab regions, which play an indispensable role in antigen recognition and one Fc region that mediates antibody effector functions, such as antibody-dependent cellular phagocytosis (ADCP), antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC) by binding to its receptor, FcyR (15–17). The target-specific binding and immune-mediated effector functions shed light on the promising role of IgG as the basic framework for engineering recombinant monoclonal antibodies.

According to variations in the length and sequence of the hinge region, and sequence variation in the Cy2 and Cy3 domains of heavy chains, human IgG antibodies are further divided into four different subtypes including IgG1, IgG2, IgG3, and IgG4, among which IgG4 is the least while IgG1 is the most (18, 19). These four subtypes share a similar structure, with ≥90% sequence homology (20). Nonetheless, single amino acid differences can give rise to unique profiles of structure and effector function among subtypes (Table 1).

IgG1 is the most abundant of the four human IgG subclasses, making up ≥50% of the total serum IgG concentration. IgG1, with a stable structure, could induce potent effector functions mediated by the Fc fragment, thus achieving cytotoxic or apoptotic responses. PD-L1 inhibitors recognize and bind to PD-L1 on tumor cells, further blocking the PD-1/PD-L1 signaling pathway. To enhance the anti-tumor response, PD-L1 inhibitors must bind to FcyR and C1q with high affinity to evoke potent ADCC and CDC to clear tumor cells, which indicates that IgG1 is the optimal structural basis of PD-L1 inhibitors. Nonetheless, in clinical development, durvalumab and atezolizumab are engineered to elicit a weakened effector function, to protect PD-1/PD-L1 double-positive immune cells and reduce potential adverse effects (23, 24). However, avelumab still maintains the capability to activate effective ADCC (25).

IgG4 is the least common IgG subclass, accounting for ~5% of the total serum IgG concentration (18). Due to its low affinity for C1q and FcyR, IgG4 only weakly induces CDC and ADCC. Typically, PD-1 inhibitors recognize and bind to PD-1 on activated T cells, thus shifting the balance to immune activation. To avoid Fc-mediated cytotoxic effects on T cells, PD-1 inhibitors are supposed to have attenuated effector functions, with low affinity for FcyR and C1q. IgG4 with a lower propensity to elicit effector functions is designed to block ligand-receptor interactions instead of killing antigen-expressing target cells,
which makes it the optimal IgG subtype to target PD-1 on T cells for a favorable anti-tumor response (26). Of particular concern, IgG4 behaves as a monovalent-bispecific antibody as a result of the in vivo exchange of IgG half-molecules, a process termed Fab-arm exchange (FAE) (22, 27). It has been demonstrated that the change of a proline (Pro) in the core hinge to a serine (Ser) leads to the formation of “intra-chain” disulfide bonds instead of “inter-chain” disulfide bonds, as well as attenuated non-covalent interactions between the heavy chains in the CH3 region, thus resulting in the dissociation and recombination of heavy chains and further generating newly bi-specific heterozygous IgG4 with reduced avidity to antigen (28–30). Therefore, the core hinge Ser228Pro (S228P) mutation is a significant design consideration for therapeutic IgG4 antibodies to abrogate FAE (31, 32).
Pembrolizumab, containing a S228P mutation, is a compact molecule with an asymmetrical Y shape and a short hinge region. The Fc domain is glycosylated at Asn297 in the CH2 domain on both chains with one CH2 domain rotated 120°, causing the corresponding glycans to face the solvent (32). Another PD-1 inhibitor, nivolumab, also with an S228P mutation, has a structure nearly identical to pembrolizumab, except for the variable regions, which serve the functions of antigen recognition and binding.

### COMPARISON IN BIOLOGICAL FUNCTION AMONG PD-1/PD-L1 INHIBITORS

#### Structural Mechanism of Action

Based on X-ray crystal structure analysis, the general interaction between PD-1 and PD-L1 is mediated mostly by the residues of the C′CFG strands within both molecules. This binding covers a buried surface area of 1,970 Å² and triggers a moderate conformational change in the PD-1 CC' loop, which makes it capable of closing around PD-L1 (21). The dissociation constant, $K_D$, is usually used to reflect the affinity of molecular interactions. Typically, a higher $K_D$ value indicates a lower affinity. $K_D$ value for PD-L1 binding to PD-L1 is $\sim$8.2 μM.

PD-1 inhibitors can competitively bind to PD-1 with PD-L1 because of sharing an overlapping binding surface. Of note, although they have a similar molecular mechanism of action, PD-1 inhibitors have significant differences with respect to how they interact with PD-1 (Table 2). Nivolumab binds to PD-1 using the residues of the N-terminal extension, accompanied by contributions from both the FG and BC loops of the IgV domain. This binding covers a buried surface area of 1,487–1,932.5 Å², with an overlapping binding area for nivolumab and PD-L1, which is mainly located on the FG loop. Notably, the N-loop, which is not involved in PD-L1 recognition, is mainly responsible for binding affinity with a correlated $K_D$ value about 3.06 nM (34). As for pembrolizumab, the interaction with PD-1 mainly depends on the flexible C′D loop of PD-1, but the C, C′, and F strands are involved as well. The total buried binding surface area is 1,774–2,126 Å², with the competing binding area of pembrolizumab and PD-L1 mainly located on the FG loop. $K_D$ value for this interaction is $\sim$29 pM, which is mainly influenced by the C′D loop (10, 35). Apart from direct occupancy, it has been demonstrated that, after binding to PD-1, both inhibitors can trigger slight conformational changes in the flexible BC and FG loops, thus further potently inhibiting PD-L1 binding (21). Of particular interest, given the fact that there is nearly no overlapping antigen binding site on PD-1 for these two inhibitors, it has been speculated that the simultaneous administration of pembrolizumab and nivolumab may have the potential for superior therapeutic efficacy. However, more research is needed to test this hypothesis.

The main interaction between PD-1 inhibitors and PD-1 is dependent on the flexible loops of PD-1, which are typically not part of the PD-1/PD-L1 binding surface. By contrast, PD-L1 inhibitors can bind to PD-L1 using the epitope that significantly overlaps with the PD-1 binding interface (36). Avelumab binds to PD-L1 via the epitope located mainly on the F and G strands of PD-L1, partially overlapping with the PD-1 binding region, with a $K_D$ value of $\sim$42 pM (37). For atezolizumab, the CDRs located in the VH chains dominate the binding, mainly by covering the CC′FG strands and residues in the BC, CC′, C′C′′, and FG loops (38). The associated $K_p$ value is $\sim$400 pM (39). In addition, the binding sites of durvalumab are mainly located in the N-terminal region, the CC′ loop and the CC′FG strands, with a $K_D$ value of about 667 pM (40). Notably, in contrast to PD-1 inhibitors, PD-L1 inhibitors do not usually induce a significant conformational change of PD-L1.

#### Immunogenicity

As protein therapeutics, antibodies are inevitably immunogenic, which induces the production of anti-drug antibodies (ADA), thus affecting the safety and efficacy by antibody-mediated neutralization or hypersensitivity responses (41, 42). Hence, immunogenicity evaluation is required for all antibodies during product engineering. Of note, the immunogenicity of antibodies is regulated by a variety of factors, including structural characteristics, manufacturing techniques, drug-delivery methods, and patient immune status, among which, structural characteristics are the most important.

To overcome the high immunogenicity of complete murine-origin antibodies, the preparation of monoclonal antibodies has gone through several evolutionary processes. Chimerization was first attempted by combining mouse antigen-binding domains with human constant region domains, to form chimeric mouse-human antibody molecules, with $\sim$67% of the primary sequence of the antibody derived from the human sequence (43). Humanization was the following development, in which the CDRs from the heavy-chain variable region of mouse IgG were grafted onto the human IgG structure, to create a humanized monoclonal antibody with $\sim$95% human-derived sequence (44). Recent technological breakthroughs have enabled the generation of human therapeutic antibodies without high immunogenicity, which has been demonstrated by the success of rituximab (27)

**Table 1 | Comparison of the four human IgG subtypes.**

| Percentage of the total IgG | IgG1 | IgG2 | IgG3 | IgG4 |
|-----------------------------|------|------|------|------|
| Amino acid in hinge region  | 60   | 25   | 10   | 5    |
| Inter-heavy chain disulfide bonds | 15   | 12   | 62   | 12   |
| Antibody-dependent cell-mediated phagocytosis (ADCP) | ++   | +/−  | ++   | +/−  |
| Antibody-dependent complement-dependent cytotoxicity (CDC) | ++   | −    | +++  | −    |
| Antibody-dependent cell-mediated phagocytosis (ADCP) | +    | +    | +    | +/−  |
| FcRn binding | Stable | Covalent dimer | Prone to protease digestion | Fab arm exchange |
| Stability (22) | Stable | Covalent dimer | Prone to protease digestion | Fab arm exchange |
| Half-life (d) | 21–23 | 20–23 | 7–8  | 21–23 |
TABLE 2 | Comparison of the different PD-1/PD-L1 inhibitors.

| Drug    | Nivolumab | Pembrolizumab | Atezolizumab | Avelumab | Durvalumab |
|---------|-----------|---------------|--------------|----------|------------|
| Subtypes | IgG4       | IgG4          | IgG1         | IgG1     | IgG1       |
| Binding area | N-loop   | C′D loop      | CC FG strands | F and G strands | the N-terminal region, the CC′ loop and the CC FG strands |
| Buried surface | 1,487–1,932.5 Å | 1,774–2,126 Å | 2,106 Å | 1,815 Å | 1,624 Å |
| Affinity | 3.06 nM | 29 pM | 1.75 nM | 0.046 nM | 0.66 nM |
| Degree of humanization | Fully human | Humanized | Fully human | Fully human | Fully human |
| Immunogenicity | 12.9% | 1.8% | NR | NR | 0.4% |
| Modification | S228P | S228P | Fc engineering | - | Fc engineering |
| Distribution | Spleen | Lung, liver, kidney, spleen | NR | NR | NR |
| Half life | 26.7 | 25.8 | 27 | 6 | 17 |
| Dosage regimen | 3 mg/kg q2w | 200 mg q3w | 1,200 mg q3w | 10 mg/kg q2w | 10 mg/kg q2w |

of fully human antibodies from transgenic mice that have been genetically engineered with the human IgG locus (45). Nivolumab, together with atezolizumab, sintilimab, avelumab, durvalumab, and tislelizumab are fully human PD-1/PD-L1-targeting monoclonal antibodies, while pembrolizumab, JS-001, and camrelizumab are humanized antibodies. It remains unclear whether fully human antibodies show lower immunogenicity compared to humanized antibodies. One certainty is that fully human antibodies do show at least some immunogenicity, possibly attributed to unique idiotypes, unique post-translational modifications, or impurities related to the manufacturing process (46).

The detection of ADAs can reflect the immunogenicity of agents to some extent. According to the instructions, in patients treated with nivolumab, 12.9% (287 of 2,232) tested positive for ADAs, while the rate of neutralizing antibody detection was ~0.7% (16 of 2,232). In patients treated with pembrolizumab, the corresponding rate of ADAs was 1.8% (36 of 2,034) with neutralizing antibodies detected at a rate of 0.4% (9 of 2,034). Moreover, in a phase 1/2 trial of stage IIIB–IV NSCLC, 3.1% (26 of 849) of patients treated with durvalumab tested positive for ADAs, while neutralizing antibodies were detected in only 0.4% of patients (3 of 849) (47). Thus, far, due to limited research, it is unclear whether treatment-emergent ADAs have any impact on the pharmacokinetics (PK), efficacy, or safety of related drugs. When comparing the rate of ADA positivity for different PD-1/PD-L1 inhibitors, in addition to the intrinsic effects of the drugs, the sensitivity and specificity of the ADA detection methods, sample handling and collection, the combination of other drugs and the underlying disease status of the patients should all be taken into consideration.

Pharmacokinetics and Dosage Regimen
Pharmacokinetic research is indispensable before a drug can be applied to clinical practice. Pharmacokinetics (PK) usually involves four fundamental aspects: absorption, distribution, metabolism, and elimination. As macromolecule-protein biologics, PD-1/PD-L1 inhibitors are administered intravenously that is considered 100% absorption. Typically, the distribution of the drugs is limited because large molecules do not spread efficiently from the blood to peripheral compartments (48). The specific metabolic mechanisms involved include hepatic metabolism and direct proteolytic degradation, with the latter playing a major role (48). In vivo non-human primate imaging using a ⁴⁸Zr-nivolumab tracer, in a study performed by Cole et al., showed that the spleen is the main organ of distribution, with primary clearance through the liver (49). While for pembrolizumab, the volume of distribution at a steady state is 7.4 L (coefficient of variation: 19%), with a consistently restricted extravascular distribution mainly concentrated in the lung, liver, kidney, and spleen.

Notably, elimination appears to play a dominant role in PK and is under the influence of various regulation such as neonatal Fc receptor (FcRn)-dependent recycling, target-mediated drug disposition (TMDD), and non-specific or off-target binding-mediated clearance, among which FcRn-dependent recycling plays a major role (50, 51). It has been demonstrated that TMDD leads to rapid clearance by inducing internalization and downstream degradation (50). On the contrary, FcRn binding to IgG via its Fc CH2-CH3 interface can rescue it from elimination, resulting in an extended half-life (52, 53). Due to restricted FcRn expression, FcRn-dependent recycling is capacity limited. It has been observed that high concentrations of IgG can saturate the FcRn recycling system, thus decreasing recycling efficiency and resulting in a significant increase in the fractional catabolic rate of IgG. This should be taken into consideration when choosing the optimal dosage regimen (50).

The antibodies currently on the market are a little different in their in vivo PK. Generally, the standard dosage regimen for clinical practice needs to be based on a comprehensive understanding of the PK. Due to different PK, the dosage regimens for PD-1 and PD-L1 blockade vary. A nivolumab dosage regimen of 3 mg/kg every 2 weeks exhibited superior efficacy while 200 mg of pembrolizumab every 3 weeks has already been defined as the standard dosage regimen for the treatment of various tumors (54–57). For atezolizumab, based
on various research data, the currently recommended dosage regimen for further clinical development is 1,200 mg (15 mg/kg) (58). To achieve a target occupancy of 90%, a dosage regimen of 10 mg/kg every 2 weeks is optimal for avelumab treatment (59). Moreover, durvalumab can achieve maximum efficacy when applied with 10 mg/kg every 2 weeks (60).

A relatively long half-life allows drugs to work in the body for a longer period, thus allowing relatively less frequent dosing. It may be possible to reduce dosing frequencies by engineering the PK of drugs to give them a relatively long half-life, which would finally make them convenient and cost-effective.

**CLINICAL COMPARISON OF PD-1/PD-L1 INHIBITORS**

**Predictive Biomarkers**

Although PD-1/PD-L1 inhibitors have made a great success in the management of a broad range of cancer types, most patients are intrinsically resistant and fail to respond well. In the era of precision treatment, it's of great significance to identify patients who are more likely to benefit from immunotherapy.

PD-L1 and tumor-mutation burden (TMB) are currently the two most promising predictive biomarkers. Generally, the overexpression of PD-L1 or a high TMB may correlate with better objective response, durable clinical benefit, and longer progression-free survival (PFS) (33, 61). However, it has been found that the predictive role of the two for different inhibitors is not identical. A PD-L1 assay is now routinely performed for cancer patients to determine whether they are eligible for pembrolizumab treatment. The KEYNOTE-024 study, together with KEYNOTE-042 study, demonstrated that a PD-L1 tumor proportion score (TPS) ≥50% should act as the cut-off value to select patients with advanced NSCLC to receive first-line pembrolizumab monotherapy, while the standard second-line pembrolizumab monotherapy requires patients to have a TPS ≥1% (57, 62). Notably, the predictive role of PD-L1 expression for nivolumab is not as effective as that for pembrolizumab. In the Checkmate-032 study, patients with recurrent or metastatic urothelial cancer who were treated with nivolumab showed no significant difference in objective response rate (ORR) between the subgroup with PD-L1 expression levels ≥1% and that <1% (24.0 vs. 26.2%, respectively) (63). Likewise, compared with chemotherapy, the CheckMate 026 study also showed no improvement in PFS or overall survival (OS) of patients with untreated stage IV or recurrent NSCLC and a PD-L1 expression level ≥5% who treated with nivolumab (mPFS 4.2 vs. 5.9 mons, p = 0.25; mOS 14.4 vs. 13.2 mons) (64). Of particular interest, subsequent exploratory analysis of this trial has shown that TMB is a good predictor for nivolumab treatment efficacy. It demonstrated that patients with a high TMB had superior mPFS and ORR with nivolumab vs. chemotherapy (9.7 vs. 5.8 months, 47 vs. 28%, respectively).

One explanation for the difference in the predictive power of PD-L1 expression between different inhibitors may be attributed to the assessment of PD-L1 expression. So far, the immunohistochemistry (IHC) assay for each inhibitors varies (65). Hence, chances are that for the same sample, the assessment of PD-L1 status may be inconsistent when conducted by different assay. Whether different IHC assays share equivalent measurement performance and interchangeably remains to be deeply investigated. In order to better select the population that would receive optimal benefit, further studies are required to determine whether PD-L1 expression and TMB are two independent biomarkers with different predictive values for different drugs. If so, what are the specific mechanisms that cause this difference? Moreover, as more and more predictive biomarkers such as mismatch-repair deficiency and tumor infiltrating immune cells, are being studied, whether they have different predictive power for different inhibitors should be taken more consideration as well.

**Clinical Efficacy**

Currently, PD-1/PD-L1 inhibitors have been approved for the treatment of various tumors, including NSCLC, melanoma, urothelial cancer, esophageal cancer, RCC, and Hodgkin's lymphoma (55, 56, 66–75). Although all PD-1/PD-L1 inhibitors work by targeting the same PD-1/PD-L1 signaling pathway, whether the clinical efficacy is comparable between different inhibitors remains unclear. In a preclinical trial, Tyler J. Curiel et al. made a direct comparison of PD-1 inhibitors and PD-L1 inhibitors to explore their efficacy in aged host treatment. The contrast revealed that PD-1 inhibitors could treat B16 tumors in aged hosts as effectively as in young hosts whereas PD-L1 inhibitors failed to exert potent anti-tumor effect in the same condition of aged hosts (76). Attention was greatly aroused whether difference of the efficacy between inhibitors exist in clinical practice.

Take the treatment of NSCLC for example, based on currently available clinical data, there are differences in clinical treatment options for each inhibitor, which are mainly attributed to the potential differences in clinical efficacy (Table 3) (55, 57, 62, 64, 66–68, 77–87). For first-line monotherapy for NSCLC, the results of the KEYNOTE-024 and KEYNOTE 042, showed that pembrolizumab has superior survival benefits, when compared with chemotherapy, in advanced NSCLC patients (57, 62). And in the latest interim OS analysis of the IMpower110, it was demonstrated that atezolizumab treatment resulted in longer PFS and OS than chemotherapy in the cohort with TC3 or IC3 of untreated metastatic NSCLC (77). However, in the phase 3 study, CheckMate 026, involving patients with previously untreated stage IV or recurrent NSCLC, nivolumab did not appreciably improve mOS when compared with chemotherapy (14.4 vs. 13.2 months, respectively) (64). Except for monotherapy, PD-1 or PD-L1 inhibitors combined with other anti-tumor treatments for first-line NSCLC therapy have also shown promising results and several combination treatments have been approved by the FDA for clinical practice. In the phase 3 KEYNOTE 189 and KEYNOTE 407 trials of patients with untreated metastatic NSCLC, pembrolizumab combined with chemotherapy resulted in significantly longer OS and PFS when compared with chemotherapy alone (78, 79). Instead of combining with chemotherapy, first-line nivolumab plus ipilimumab for advanced NSCLC treatment has been shown
# TABLE 3 | The results of recent advances in landmark trials of different PD-1/PD-L1 inhibitors for the treatment of lung cancer.

| Drugs                  | Trials                      | NCT number | Patients | Trial design                                                                 | Efficacy and safety | AE3-5 | References |
|------------------------|-----------------------------|------------|----------|-------------------------------------------------------------------------------|---------------------|-------|------------|
| **First-line monotherapy** |                            |            |          |                                                                               |                     |       |            |
| Pembrolizumab          | KEYNOTE-024                 | NCT02142738| 305      | Pembrolizumab vs. platinum-based chemotherapy (PD-L1 >50%)                    | 44.8 vs. 27.8%      | mPFS  | estimated 6-mons OS 80.2 vs. 72.4% p = 0.005 | 26.6 vs. 53.3% (57) |
|                        | KEYNOTE-042                 | NCT02220894| 1,274    | Pembrolizumab vs. platinum-based chemotherapy (PD-L1 >1%)                    | 27 vs. 27%          | mPFS  | mOS 16.7 vs. 12.1 p = 0.0018               | 18 vs. 41% (62)       |
| Atezolizumab           | IMpower-110                 | NCT02409342| 572      | Atezolizumab vs. platinum-based chemotherapy (TC3 or IC3)                    | 38.3 vs. 27.6%     | 6-mons PFS | mOS 20.2 vs. 13.1 p = 0.0106               | 31.8 vs. 53.6% (77) |
| Nivolumab              | CheckMate 026               | NCT02041533| 423      | Nivolumab vs. platinum-based chemotherapy (PD-L1 >5%)                        | 26 vs. 33%          | mPFS  | mOS 14.4 vs. 13.2                         | 18 vs. 51% (64)       |
| **First-line combination therapy** |                            |            |          |                                                                               |                     |       |            |
| Pembrolizumab          | KEYNOTE-189                 | NCT02578680| 616      | Pembrolizumab+chemotherapy vs. chemotherapy                                  | 47.6 vs. 18.9%     | mPFS  | Estimated 1-year OS 69.2 vs. 49.4% p = 0.001 | 67.2 vs. 65.8% (73)   |
|                        | KEYNOTE-407                 | NCT02775435| 559      | Pembrolizumab+chemotherapy vs. chemotherapy                                  | 57.9 vs. 38.4%     | mPFS  | mOS 15.9 vs. 11.3 p = 0.001               | 69.8 vs. 68.2% (79)   |
| Nivolumab              | CheckMate 227               | NCT02477826| 1,739    | Nivolumab+ipilimumab vs. chemotherapy                                        | 45.3 vs. 26.9%     | mPFS  | NR                                       | 31.2 vs. 36.1% (80)   |
| Atezolizumab           | IMpower-130                 | NCT02367781| 723      | Atezolizumab+chemotherapy vs. chemotherapy                                   | 49.2 vs. 31.9%     | mPFS  | mOS 18.6 vs. 13.9 p = 0.033              | 81 vs. 71% (81)       |
|                        | IMpower-131                 | NCT02367794| 1,021    | Atezolizumab+chemotherapy vs. chemotherapy                                   | NR                  | mPFS  | mOS 14.2 vs. 13.5                         | 68 vs. 57% (82)       |
|                        | IMpower-132                 | NCT02667434| 578      | Atezolizumab+chemotherapy vs. chemotherapy                                   | 47 vs. 32%         | mPFS  | 1-year-OS 59.6 vs. 55.4% p = 0.033       | 69 vs. 59% (83)       |
|                        | IMpower-150                 | NCT02366143| 692      | Atezolizumab+chemotherapy+bevacizumab vs. chemotherapy                       | 63.5 vs. 48.0%     | mPFS  | mOS 58.5 vs. 50.0%                        | 58.5 vs. 50.0% (84)   |

(Continued)
| Drugs          | Trials     | NCT number     | Patients | Trial design | Efficacy and safety | References |
|---------------|------------|----------------|----------|--------------|---------------------|------------|
|               |            |                |          |              | ORR     | PFS     | OS      | AE3-5 |          |
| **Second-line therapy** |            |                |          |              |         |         |         |       |          |
| Pembrolizumab | KEYNOTE-   | NCT01905657    | 1,034    | pembrolizumab 2 mg/kg vs. docetaxel; pembrolizumab 10 mg/kg vs. docetaxel | 18 vs. 9%; 18 vs. 9% | mPFS 3.9 vs 4.0; 4.0 vs. 4.0 | mOS 10.4 vs 8.5; PD-L1 >50% OS | 13 vs. 16%; (55) |
|               | 010        |                |          |              | PD-L1 >50% 30 vs. 8%; 29 vs. 8% | 0.004; 0.0001; 0.0001 | 5.2 vs. 4.1 | 14.9 vs. 8.2 | 17.3 vs. 8.2 |
| Nivolumab     | CheckMate  | NCT01642004    | 272      | Nivolumab vs. docetaxel | 20 vs. 9% | mPFS 3.5 vs 2.8 | mOS 9.2 vs 6.0 | 10 vs. 57% (66) |
|               | 017        |                |          |              | ρ = 0.0083 = 0.0083 | p < 0.001 |         | ρ < 0.001 |       |
|               | CheckMate  | NCT01673867    | 582      | Nivolumab vs. docetaxel | 19% vs. 12% | mPFS 2.3 vs 4.2 | mOS 12.2 vs 9.4 | 10 vs. 54% (67) |
|               | 057        |                |          |              | ρ = 0.02 |         | ρ = 0.002 |         |
|               | CheckMate  | NCT02613507    | 504      | Nivolumab vs. docetaxel | 16.6 vs. 4.2% | mPFS 2.8 vs 2.8 | mOS 12.0 vs 9.6 | 10 vs. 48% (65) |
|               | 078        |                |          |              | ρ < 0.0001 | p = 0.0147 | p = 0.0006 |       |
| Atezolizumab  | OAK        | NCT02008227    | 1,225    | Atezolizumab vs. docetaxel | 14 vs. 13% | mPFS 2.8 vs 4.0 | mOS 13.8 vs 9.6 | 15 vs. 43% (68) |
|               | POPLAR     | NCT01903993    | 287      | Atezolizumab vs. docetaxel | 57 vs. 24% in the TC3 or IC3 subgroup 38 vs. 13% | mPFS 2.7 vs 3.0 in the TC3 or IC3 subgroup 7.8 vs 3.9 | mOS 12.6 vs 9.7; PD-L1 >50% OS | 11 vs. 39% (66) |
| Avelumab      | JAVELIN    | NCT02395172    | 792      | Avelumab vs. docetaxel (PD-L1-positive) | 19 vs. 12% | mPFS 3.4 vs 4.1 | mOS 11.4 vs 10.3 | 10 vs. 49% (67) |
| Lung 200      |            |                |          |              | ρ = 0.011 | p = 0.53 | ρ = 0.16 |       |
to have obvious survival benefits as well, with significantly longer PFS and improved ORR (7.2 vs. 5.5 mons, 45.3 vs. 26.9%, respectively) (80). However, the published IMPower131 and IMPower132 trial of atezolizumab showed no statistically significant difference in OS (82, 83). Of particular concern, a further comparison of the KEYNOTE407 and IMPower131 studies showed that pembrolizumab plus chemotherapy led to superior OS and PFS than atezolizumab plus chemotherapy, especially in PD-L1-low/negative patients. Notably, until now, nivolumab, pembrolizumab, and atezolizumab have all been widely used for second-line treatment of patients with disease recurrence or progression after prior platinum-based regimens and this treatment strategy has achieved impressive survival benefits (Table 3) (55, 56, 66–68). However, it has been observed that avelumab does not improve survival compared with docetaxel, in patients with prior platinum-treated PD-L1-positive NSCLC (87).

Several pooled analyses have made indirect comparisons among PD-1/PD-L1 inhibitors. A comparative analysis by Pillai et al. showed that the ORR in the population treated with PD-1 inhibitors was not significantly different from that in the group treated with PD-L1 inhibitors (19 vs. 18.6%; p = 0.17) (88). However, a meta-analysis of five trials demonstrated that nivolumab and pembrolizumab exhibit a superior ORR compared to atezolizumab (89). Nonetheless, they are not remarkably different in either PFS or OS. A pooled statistical analysis of randomized, controlled trials performed by Carbognin et al. indirectly compared the efficacy of PD-1 inhibitors in the treatment of NSCLC, advanced melanoma and genitourinary cancer. The results showed that the ORRs of nivolumab-treated patients in PD-L1-positive and -negative subgroups were 39.3% (34.1–44.4%) and 22.9% (19.4–26.3%), respectively, while the corresponding rates in pembrolizumab-treated patients were 30.3% (25.2–35.3%) and 10.8% (3.3–18.4%), respectively (90). Moreover, in a pooled analysis of second- or later-line treatment of nasopharyngeal cancer, camrelizumab (34.1%) exhibited the highest ORR, followed by pembrolizumab (26.3%), JS001 (23.3%), and nivolumab (19.0%) (91). Besides, Duan J et al. conducted a meta-analysis with an adjusted mirror principal to explore the potential differences in PD-1/PD-L1 inhibitors. It showed that PD-1 inhibitors could achieve superior survival outcomes than PD-L1 inhibitors in patients with solid tumors irrespective of monotherapy, or combination treatment (92).

Although limited data obtained from large-scale clinical trials have provided some valuable information, no head-to-head clinical study has been performed to directly compare the efficacy of each PD-1/PD-L1 inhibitor. The inconsistencies in the reported clinical efficacy of PD-1/PD-L1 inhibitors warrants further investigation to determine whether these differences are drug-dependent or drug-independent, or are attributed to discrepancies in trial design or execution, or occur just by chance.

Safety
In addition to escaping immune surveillance and developing malignancies, the PD-1/PD-L1 pathway can also mediate immunological homoeostasis (93). Therefore, while studying the anti-tumor benefits of PD-1/PD-L1 inhibitors, attention must be paid to the accompanying immune-related adverse effects (AEs). Immune-related AEs have been observed for nearly all of the PD-1/PD-L1 inhibitors (Table 3). They include fatigue, decreased appetite, diarrhea, hypothyroidism, hyperthyroidism, pneumonitis, skin reactions, and colitis (91, 94). In addition to excessive immune activation, another important cause of antibody-induced AEs is off-target binding. The antibodies are likely to cross-bind to functionally distinct, but structurally similar targets, leading to unexpected responses. However, when compared with traditional treatments, such as chemotherapy, PD-1/PD-L1 inhibitors have a significantly lower incidence of AEs. Typically, immune-related AEs are well-controlled by symptomatic treatment. Nonetheless, severe, fatal AEs can occur (95).

Nivolumab has been shown to have a narrow and mild toxicity spectrum, mainly causing endocrine toxicities (96). Atezolizumab is associated with a relatively high risk of developing hypothyroidism, nausea, and vomiting. Arthralgia, pneumonitis, and hepatic toxicities are the most common AEs caused by pembrolizumab (96), whereas for sintilimab, the most frequently reported AEs are hypothyroidism, increased blood thyroid-stimulating hormone levels, and decreased free thyroxine levels (3). Of particular concern, the PD-1 inhibitor, camrelizumab (SHR-1210), has been observed to have a highly specific AE known as capillary hemangioma, which appears after the initiation of treatment and regresses spontaneously both during and after treatment, with no remarkable effects on the anti-tumor efficacy or safety of the drug (97).

A pooled analysis performed by Xu et al. showed that the incidence of grade 1–5 AEs is 66.4, 71.8, and 75.1% for atezolizumab, nivolumab, and pembrolizumab, respectively, while the corresponding grade 3 or 4 AE incidence is 15.1, 14.1, and 19.8%, respectively (96). Moreover, a pooled analysis of nasopharyngeal cancer patients showed that the incidence rates of grade 1–5/3–5 AEs are 74.1/29.6, 54.2/17.4, 92.3/24.5, and 96.8/16.1% for pembrolizumab, nivolumab, JS001, and camrelizumab, respectively. This further indicates that, with respect to grade 1–5 AEs, nivolumab and pembrolizumab may be superior options, but when considering grade 3–5 AEs, camrelizumab and nivolumab show more favorable safety (91).

Due to limited data, population-based studies or large-scale head-to-head comparative trials are warranted to determine whether there are differences in the incidence and severity of AEs among different PD-1/PD-L1 inhibitors.

CONCLUSION
As an increasing number of PD-1/PD-L1 inhibitors are used for the clinical treatment of cancer, there is a growing concern about whether they are comparable. It is well-known that both PD-1 inhibitors and PD-L1 inhibitors share the same rationale, in that they work by targeting and blocking the PD-1/PD-L1 signaling pathway. Nonetheless, these inhibitors are not completely interchangeable in clinical applications.

Based on the specific requirements of their effector functions, PD-1 inhibitors and PD-L1 inhibitors have a different structural...
basis, namely IgG4 and IgG1, respectively. Even with the same structural basis, it has been shown that characteristics such as the binding site, binding area, and binding affinity vary among the inhibitors. Although influenced by various factors, especially the degree of humanization, whether there is a significant difference in immunogenicity among inhibitors remains to be further studied. Moreover, the comparison of the clinical applications of these inhibitors, including predictive biomarkers, clinical efficacy, and safety provides insights for the design of future clinical research. In the era of precision medicine, in order to better select the population that will achieve optimal benefit, further studies are required to determine whether PD-L1 expression and TMB are two independent biomarkers with different predictive value for different drugs. Currently, clinical trials have shown significant differences in the selection of the therapeutic application and the corresponding efficacy of various inhibitors. Pooled analyses also revealed possible differences in clinical efficacy among the inhibitors. However, these indirect, non-head-to-head comparisons have certain limitations. It has been demonstrated that most inhibitors are well-tolerated, with nearly similar toxicity spectra. Nonetheless, the incidence and severity of various AEs associated with each inhibitor may vary to some extent. Whether this difference has remarkable clinical significance requires further investigation.

In summary, with the limited data available, this review compares the currently approved PD-1/PD-L1 inhibitors and provides some direction for future clinical studies. Population-based studies or large-scale head-to-head comparative trials are warranted to gain a more in-depth understanding of whether there are significant differences among PD-1/PD-L1 inhibitors and whether these potential differences directly affect their efficacy and safety, thus influencing the choice of the optimal population for clinical application.

**AUTHOR CONTRIBUTIONS**

XM designed the study, edited and approved final manuscript. JY made critical appraisal and approved final manuscript. JL, YP, and ZH collected the materials and drafted the article. All authors read and approved the final manuscript and contributed in the preparation of this work.

**FUNDING**

The study was funded by National Natural Science Foundation of China (No. 81972796) and Natural Science Foundation of Shandong (No. ZR2019MH010).

**REFERENCES**

1. Bardhan K, Anagnostou T, Boussiotis VA. The PD1:PD-L1/2 pathway from discovery to clinical implementation. *Front Immunol.* (2016) 7:550. doi: 10.3389/fimmu.2016.00550
2. Song Y, Gao Q, Zhang H, Fan L, Zhou J, Zou D, et al. Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study. *Leukemia.* (2020) 34:533–42. doi: 10.1038/s41373-019-01545-2
3. Shi Y, Su H, Song Y, Jiang W, Sun X, Qian W, et al. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. *Lancet Haematol.* (2019) 6:e12–9. doi: 10.1016/S2352-3026(18)30192-3
4. Fu J, Wang F, Dong LH, Zhang J, Deng CL, Wang XL, et al. Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody. *Acta Pharmacol Sin.* (2017) 38:710–18. doi: 10.1038/aps.2016.161
5. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. *Annu Rev Immunol.* (2008) 26:677–704. doi: 10.1146/annurev.immunol.26.021607.090331
6. Cheng X, Veverka R, Radhakrishnan A, Waters LC, Muskett FW, Morgan SH, et al. Structure and interactions of the human programmed cell death 1 receptor. *J Biol Chem.* (2013) 288:11771–85. doi: 10.1074/jbc.M112.448126
7. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. *Immunol Rev.* (2010) 236:219–42. doi: 10.1111/j.1600-065X.2010.00923.x
8. Park JJ, Omiya R, Matsumura Y, Sakoda Y, Kuramasu A, Augustine MM, et al. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. *Blood.* (2010) 116:1291–8. doi: 10.1182/blood-2010-01-265975
9. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, et al. Tumor antigen-specific CD8+ T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. *Blood.* (2009) 114:1537–44. doi: 10.1182/blood-2008-12-195792
10. Na Z, Yeo SP, Bharath SR, Bowler MW, Balicci E, Wang CL, et al. Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab. *Cell Res.* (2017) 27:147–50. doi: 10.1038/cr.2016.77
11. Alsaab HO, Sa S, Alzharni R, Tatiparti K, Bhise K, Kashaw SK, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. *Front Pharmacol.* (2017) 8:561. doi: 10.3389/fphar.2017.00561
12. Fang W, Yang Y, Ma Y, Hong S, Lin L, He X, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. *Lancet Oncol.* (2018) 19:1338–50. doi: 10.1016/S1470-2045(18)30495-9
13. Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1. *Clin Cancer Res.* (2012) 18:6580–7. doi: 10.1158/1078-0432.CCR-12-1362
14. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. *Immunol. (2007) 27:111–22. doi: 10.1016/j.imunni.2007.05.016
15. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. *Nat Rev Immunol.* (2008) 8:34–47. doi: 10.1038/nri2206
16. Sibérol S, Dutertre CA, Fridman WH, Teillaud JL. FcgammaR: the key to optimize therapeutic antibodies? *Crit Rev Oncol Hematol.* (2007) 62:26–33. doi: 10.1016/j.critrevonc.2006.12.003
17. Almagro JC, Daniels-Wells TR, Perez-Tapia SM, Penichet ML. Progress and challenges in the design and clinical development of antibodies for cancer therapy. *Front Immunol.* (2018) 9:1751. doi: 10.3389/fimmu.2017.01751
18. Alberse RC, Stapel SO, Schuurman J, Rispens T. Immunoglobulin G4: an odd antibody. *Clin Exp Allergy.* (2009) 39:469–77. doi: 10.1111/j.1365-2222.2009.03207.x
19. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. *Front Immunol.* (2014) 5:520. doi: 10.3389/fimmu.2014.00520
20. Koneczny I. A new classification system for IgG4 autoantibodies. *Front Immunol.* (2018) 9:97. doi: 10.3389/fimmu.2018.00097
21. Zak KM, Kitel R, Przetocka S, Golik P, Guxik K, Musielak B, et al. Structure of the complex of programmed death-1, PD-1, and its ligand PD-L1. Structure. (2015) 23:2341–8. doi: 10.1016/j.str.2015.09.010
22. Yang D, Kroe-Barrett R, Singh S, Roberts CJ, Laue TM. IgG cooperativity - is there allostery? Implications for antibody functions and therapeutic antibody development. Mabs. (2017) 9:1231–52. doi: 10.1080/19420662.2017.1367074
23. Boyerinas B, Jochems F, Fantini M, Heery CR, Gulley JL, Tsang KY, et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res. (2015) 3:1148–57. doi: 10.1185/2326-6066.CIR-15-0059
24. Ibrahim R, Stewart R, Shahabi A. PD-L1 blockade for cancer treatment: MEDI4736. Semin Oncol. (2015) 42:474–83. doi: 10.1053/j.seminoncol.2015.02.007
25. Alvarez-Argote J, Dasanu CA. Durvalumab in cancer medicine: a comprehensive review. Expert Opin Biol Ther. (2019) 19:927–35. doi: 10.1080/14712598.2019.1635115
26. Brudin P, Iannacconti B, England P, Mancardi DA, Fernandez N, Jorieux S, et al. Specificity and affinity of human IgG4 receptors and their polymorphic variants for human IgG subclasses. Blood. (2009) 113:3716–25. doi: 10.1182/blood-2008-09-179754
27. van der Neut Kolfshoten M, Schuurman J, Losen M, Bleeker WK, Martinez-Martinez P, Vermeulen E, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic fab arm exchange. Science. (2007) 317:1554–7. doi: 10.1126/science.1144663
28. Bloom JW, Madanat MS, Marriott D, Wong T, Chan SY. Intrachain disulfide bond in the core hinge region of human IgG4. Proteins Sci. (1997) 6:407–15. doi: 10.1002/pro.5600060217
29. Schuurman J, Perdok GJ, Gorder RT, Aalberse RC. The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds. Mol Immunol. (2001) 38:1–8. doi: 10.1016/S0161-5890(01)00050-5
30. Labrijn AF, Rispen T, Meesters J, Rose RJ, den Bleker TH, Louter V, et al. Association of PD-1/PD-L1 Inhibitors with endogenous human IgG4. Thorpe SJ, et al. Therapeutic IgG4 antibodies engage in fab-arm exchange by affecting the noncovalent CH3-CH3 interaction. J Immunol. (2011) 187:3238–46. doi: 10.4049/jimmunol.100336
31. Labrijn AF, Buijsse AO, van den Bremer ET, Laue TM, Guxik K, Musielak B, et al. Structure of the complex of programmed death-1, PD-1, and its ligand PD-L1. Structure. (2015) 23:2341–8. doi: 10.1016/j.str.2015.09.010
32. Yang D, Kroe-Barrett R, Singh S, Roberts CJ, Laue TM. IgG cooperativity - is there allostery? Implications for antibody functions and therapeutic antibody development. Mabs. (2017) 9:1231–52. doi: 10.1080/19420662.2017.1367074
33. Boyerinas B, Jochems F, Fantini M, Heery CR, Gulley JL, Tsang KY, et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res. (2015) 3:1148–57. doi: 10.1185/2326-6066.CIR-15-0059
34. Ibrahim R, Stewart R, Shahabi A. PD-L1 blockade for cancer treatment: MEDI4736. Semin Oncol. (2015) 42:474–83. doi: 10.1053/j.seminoncol.2015.02.007
35. Alvarezd-Argote J, Dasanu CA. Durvalumab in cancer medicine: a comprehensive review. Expert Opin Biol Ther. (2019) 19:927–35. doi: 10.1080/14712598.2019.1635115
36. Brudin P, Iannacconti B, England P, Mancardi DA, Fernandez N, Jorieux S, et al. Specificity and affinity of human IgG4 receptors and their polymorphic variants for human IgG subclasses. Blood. (2009) 113:3716–25. doi: 10.1182/blood-2008-09-179754
37. van der Neut Kolfshoten M, Schuurman J, Losen M, Bleeker WK, Martinez-Martinez P, Vermeulen E, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic fab arm exchange. Science. (2007) 317:1554–7. doi: 10.1126/science.1144663
38. Bloom JW, Madanat MS, Marriott D, Wong T, Chan SY. Intrachain disulfide bond in the core hinge region of human IgG4. Proteins Sci. (1997) 6:407–15. doi: 10.1002/pro.5600060217
39. Schuurman J, Perdok GJ, Gorder RT, Aalberse RC. The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds. Mol Immunol. (2001) 38:1–8. doi: 10.1016/S0161-5890(01)00050-5
40. Labrijn AF, Rispen T, Meesters J, Rose RJ, den Bleker TH, Louter V, et al. Association of PD-1/PD-L1 Inhibitors with endogenous human IgG4. Thorpe SJ, et al. Therapeutic IgG4 antibodies engage in fab-arm exchange by affecting the noncovalent CH3-CH3 interaction. J Immunol. (2011) 187:3238–46. doi: 10.4049/jimmunol.100336
41. Piché-Nicholas NM, Avery LB, King AC, Kavosi M, Wang M, O’Hara DM, et al. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics. Mabs. (2018) 10:81–94. doi: 10.1080/19420662.2017.1389355
42. Saltéd JG. Isotype selection in antibody engineering. Nat Biotechnol. (2007) 25:1369–72. doi: 10.1038/nbt1207-1369
43. Aalberse RC, Schuurman J. IgG4 breaking the rules. Immunology. (2002) 105:9–19. doi: 10.1046/j.1365-2567.2001.01341.x
44. Agrawal S, Feng Y, Roy A, Kollia G, Lestini B. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. J Immunother Cancer. (2016) 4:72. doi: 10.1186/s40425-016-0177-2
45. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1–positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. (2016) 387:1540–50. doi: 10.1016/S0140-6736(15)01281-7
46. Sül J, Blumenthal GM, Fang X, He K, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1. Oncologist. (2016) 21:643–50. doi: 10.1634/theoncologist.2015-0498
47. Beck M, Rodríguez-Abreu D, Robinson AG, Hui R, Cooszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non-small-cell lung cancer. N Engl J Med. (2016) 375:1823–33. doi: 10.1056/NEJMoa1606774
48. Sheng J, Srivastava S, Sanghavi K, Lu Z, Schmidt BJ, Bello A, et al. Clinical pharmacology considerations for the development of immune checkpoint inhibitors. J Clin Pharmacol. (2017) 57(Suppl. 10):S26–S40. doi: 10.1177/0021972717710061
49. Heery CR, O’Sullivan-Coyne G, Madan RA, Cordes L, Rajan A, Rauchhorst M, et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN solid tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol. (2017) 18:587–98. doi: 10.1016/S1470-2045(17)30239-5
93. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. (2012) 12:252–64. doi: 10.1038/nrc3239

94. Chen R, Hou X, Yang L, Zhao D. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: a systematic review and meta-analysis. Thorac Cancer. (2019) 10:607–23. doi: 10.1111/1759-7714.12971

95. Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. (2016) 54:139–48. doi: 10.1016/j.ejca.2015.11.016

96. Xu C, Chen YP, Du XJ, Liu JQ, Huang CL, Chen L, et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ. (2018) 363:k4226. doi: 10.1136/bmj.k4226

97. Mo H, Huang J, Xu J, Chen X, Wu D, Qu D, et al. Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study. Br J Cancer. (2018) 119:538–45. doi: 10.1038/s41416-018-0100-3

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Chen, Pei, Luo, Huang, Yu and Meng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.